T2 Biosystems Shares Research from Industry Conferences

T2 Biosystems Inc., a leader in the rapid detection of sepsis-causing pathogens, has announced poster session and abstract data showcasing results of its rapid diagnostic technologies at several industry conferences throughout Sepsis Awareness Month.
 
“We are committed to the generation of clinical data to support the adoption and utilization of our rapid diagnostic technology, especially when it comes to bloodstream infections (BSI) and sepsis,” said John Sperzel, chairman and CEO at T2 Biosystems. “In recent weeks, compelling new data has been shared with the medical community to continue critical discussions on the importance of culture-independent rapid diagnostics in timely and accurate detection of sepsis-causing pathogens as well as patient and healthcare outcomes.”
 
Across three industry conferences in September – the American Association for Clinical Chemistry’s (AACC) Annual Scientific Meeting and Clinical Lab Expo; the College of American Pathologists’ Annual Meeting (CAP21); and IDWeek – T2 Biosystems unveiled data about forward-thinking healthcare and the importance of the rapid detection of sepsis-causing pathogens. The content, which is now available online, includes:
 

Impact of Blood Culture-Independent Rapid Diagnostics on Early Identification of Sepsis-Causing Pathogens – Presented by Aparna Ahuja, MD, Chief Medical Officer at T2 Biosystems.

• Literature review evaluating the impact of T2MR culture-independent rapid diagnostics on accuracy of lab results, time to diagnosis of blood stream infections, impact on patientcare outcomes.
• Results show T2Candida and T2Bacteria Panels provide rapid, specific and sensitive detection of bloodstream infections caused by pathogens commonly implicated in BSI that progress to sepsis.
• Performance of both assays demonstrated high accuracy with overall sensitivity and specificity of T2Candida at 91.1% and 99.4% and T2Bacteria at 90% and 98%, respectively.
• T2 Panels provided opportunity to initiate faster targeted therapy, de-escalation, shorter ICU and hospital length of stay and antimicrobial cost savings.

Performance of the T2Resistance Panel in Whole Blood, and Implications for Improving Appropriate Therapy of Bloodstream Infections – Presented by Abigail Skeel, Researcher at University of Pittsburgh.

• Evaluation of the performance of the T2Resistance Panel in detecting targeted resistance markers in patients with bloodstream infections due to ESKAPE pathogens and the potential impact on time to appropriate antibiotic therapy.
• The T2Resistance Panel demonstrated sensitivity of 92% to 100% and specificity of 99% to 100% as compared to sequencing, detected resistance determinants in three to seven hours, and has the potential to significantly shorten time to appropriate antibiotics.

Development of a Rapid, High Sensitivity, Direct from Blood Assay for Identification of Biothreat Organisms – Presented by Robert Shivers, PhD, Director of Microbiology at T2 Biosystems.

• Discussion of the development of an in vitro diagnostic assay for the identification of biothreat organisms direct from a patient blood sample.
• Achievement of sensitive and specific detection of six CDC Category A or Category B bacterial biothreat species directly from blood samples in less than five hours using T2 Biosystems’ T2Dx Instrument.

T2SARS-CoV-2 Panel is Able to Detect All SARS-CoV-2 Variants as Confirmed by Genomic Surveillance – Presented by Nabuan Naufer, scientist at T2 Biosystems.

• Review of the analysis of SARS-CoV-2 sequences confirms that the Company’s T2SARS-CoV-2 Panel detects all currently documented COVID-19 variants, resulting in a routine screening methodology to confirm detection of emerging novel variants.

Utilization of a Novel Diagnostic Assay to Improve Turnaround Time and Accurate Diagnosis and Treatment of Secondary Candidemia in a Critically Ill Immunosuppressed COVID-19 Patient – Presented by Ashley Cubillos, PharmD at Lee Health.

• Case study highlights the utilization of the T2Candida Panel for timely and accurate diagnosis of candidemia in a critically ill patient with COVID-19 resulting in rapid initiation of targeted antifungal therapy and a positive outcome for the patient.